IL139169A0 - Pyrazole derivatives as p-38 map kinase inhibitors - Google Patents

Pyrazole derivatives as p-38 map kinase inhibitors

Info

Publication number: IL139169A0
Authority: IL; Israel
Prior art keywords: kinase inhibitors; map kinase; pyrazole derivatives; methods; derivatives
Prior art date: 1998-05-05

Application number

IL13916999A

Other languages

English (en)

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-05-05

Filing date

1999-04-28

Publication date

2001-11-25

1999-04-28 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2001-11-25 Publication of IL139169A0 publication Critical patent/IL139169A0/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
- C07D231/52—Oxygen atom in position 3 and nitrogen atom in position 5, or vice versa
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Cardiology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Hematology (AREA)
Endocrinology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Immunology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

IL13916999A 1998-05-05 1999-04-28 Pyrazole derivatives as p-38 map kinase inhibitors IL139169A0 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US8425098P	1998-05-05	1998-05-05
US12241099P	1999-03-02	1999-03-02
PCT/EP1999/002879 WO1999057101A1 (en)	1998-05-05	1999-04-28	Pyrazole derivatives as p-38 map kinase inhibitors

Publications (1)

Publication Number	Publication Date
IL139169A0 true IL139169A0 (en)	2001-11-25

Family

ID=26770756

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL13916999A IL139169A0 (en)	1998-05-05	1999-04-28	Pyrazole derivatives as p-38 map kinase inhibitors

Country Status (22)

Country	Link
EP (1)	EP1075467B1 (xx)
JP (1)	JP3590586B2 (xx)
KR (1)	KR100404256B1 (xx)
CN (1)	CN1147476C (xx)
AT (1)	ATE292118T1 (xx)
AU (1)	AU765030B2 (xx)
BR (1)	BR9911013A (xx)
CA (1)	CA2329065A1 (xx)
DE (1)	DE69924480D1 (xx)
HR (1)	HRP20000724A2 (xx)
HU (1)	HUP0101581A3 (xx)
ID (1)	ID27535A (xx)
IL (1)	IL139169A0 (xx)
MA (1)	MA26627A1 (xx)
NO (1)	NO317985B1 (xx)
NZ (1)	NZ507558A (xx)
PL (1)	PL344004A1 (xx)
RU (1)	RU2000130199A (xx)
TR (1)	TR200003256T2 (xx)
TW (1)	TW593282B (xx)
WO (1)	WO1999057101A1 (xx)
YU (1)	YU67600A (xx)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1998056377A1 (en)	1997-06-13	1998-12-17	Smithkline Beecham Corporation	Novel pyrazole and pyrazoline substituted compounds
US7301021B2 (en)	1997-07-02	2007-11-27	Smithkline Beecham Corporation	Substituted imidazole compounds
US6316466B1 (en) *	1998-05-05	2001-11-13	Syntex (U.S.A.) Llc	Pyrazole derivatives P-38 MAP kinase inhibitors
US6858617B2 (en)	1998-05-26	2005-02-22	Smithkline Beecham Corporation	Substituted imidazole compounds
EP1126852B1 (en)	1998-11-04	2004-01-21	SmithKline Beecham Corporation	Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
IL143236A0 (en) *	1998-12-16	2002-04-21	Warner Lambert Co	Treatment of arthritis with mek inhibitors
US7125875B2 (en)	1999-04-15	2006-10-24	Bristol-Myers Squibb Company	Cyclic protein tyrosine kinase inhibitors
CN1348370A (zh)	1999-04-15	2002-05-08	布里斯托尔-迈尔斯斯奎布公司	环状蛋白酪氨酸激酶抑制剂
US6399621B1 (en)	1999-08-10	2002-06-04	American Cyanamid Company	N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1, 5-α]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto
US6472528B1 (en) *	1999-08-10	2002-10-29	Neurocrine Biosciences, Inc.	Synthesis of substituted pyrazolopyrimidines
US6485746B1 (en)	2000-08-25	2002-11-26	Neurocrine Biosciences, Inc.	Controlled-release sedative-hypnotic compositions and methods related thereto
US6384221B1 (en)	1999-09-02	2002-05-07	Neurocrine Biosciences, Inc.	Polymorphs of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-α]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto
ES2230171T3 (es)	1999-11-23	2005-05-01	Smithkline Beecham Corporation	Compuestos 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de csbp/p38 quinasa.
JP2003514900A (ja)	1999-11-23	2003-04-22	スミスクライン・ビーチャム・コーポレイション	ＣＳＢＰ／ｐ３８キナーゼ阻害剤としての３，４−ジヒドロ−（１Ｈ）−キナゾリン−２−オン化合物
EP1233950B1 (en)	1999-11-23	2005-10-05	Smithkline Beecham Corporation	3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/P39 kINASE INHIBITORS
AU784813B2 (en) *	2000-01-17	2006-06-29	Bayer Aktiengesellschaft	Substituted aryl ketones
US7235551B2 (en)	2000-03-02	2007-06-26	Smithkline Beecham Corporation	1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
AU3217501A (en)	2000-03-03	2001-09-12	Pfizer Prod Inc	Pyrazole ether derivatives as anti-inflammatory/analgesic agents
JP4960565B2 (ja) *	2000-05-12	2012-06-27	ジェンザイムコーポレーション	ＴＮＦαシグナル伝達のモジュレータ
GB0016787D0 (en)	2000-07-07	2000-08-30	Pfizer Ltd	Compounds useful in therapy
WO2002014305A2 (en)	2000-08-17	2002-02-21	Lumera Corporation	Design and synthesis of advanced nlo materials for electro-optic applications
CZ20022642A3 (cs) *	2001-08-27	2003-09-17	Pfizer Products Inc.	Způsob výroby dialkylpyridylboranů
PL373115A1 (en)	2001-08-30	2005-08-08	F.Hoffmann-La Roche Ag	Aminopyrrole compounds as antiinflammatory agents
JP2005538066A (ja)	2002-07-09	2005-12-15	ベーリンガーインゲルハイムファルマゲゼルシャフトミットベシュレンクテルハフツングウントコンパニーコマンディトゲゼルシャフト	新規な抗コリン作用薬及びｐ３８キナーゼ阻害剤を用いた新規な医薬組成物
US7268139B2 (en)	2002-08-29	2007-09-11	Scios, Inc.	Methods of promoting osteogenesis
EP1553096B1 (en)	2002-09-25	2012-10-31	Ube Industries, Ltd.	Pyrazole compounds
HRP20110757T1 (hr) *	2003-06-26	2011-11-30	Novartis Ag	Inhibitori kinaze p38 bazirani na 5-članom heterociklu
RU2381219C2 (ru) *	2003-06-26	2010-02-10	Новартис Аг	ПРОИЗВОДНЫЕ 5-ЧЛЕННЫХ ГЕТЕРОЦИКЛОВ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ p38
US7244441B2 (en)	2003-09-25	2007-07-17	Scios, Inc.	Stents and intra-luminal prostheses containing map kinase inhibitors
RU2419612C2 (ru) *	2003-12-23	2011-05-27	Астекс Терапьютикс Лимитед	Производные пиразола в качестве модуляторов протеинкиназы
JP2008500991A (ja) *	2004-05-29	2008-01-17	７ティーエムファーマエイ／エス	医学的使用のためのｃｒｔｈ２レセプターリガンド
US20060035893A1 (en)	2004-08-07	2006-02-16	Boehringer Ingelheim International Gmbh	Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (es)	2004-12-24	2006-10-06	Boehringer Ingelheim Int	Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
GB0513297D0 (en) *	2005-06-29	2005-08-03	Glaxo Group Ltd	Novel compounds
GB0603684D0 (en) *	2006-02-23	2006-04-05	Novartis Ag	Organic compounds
WO2008000777A2 (en) *	2006-06-29	2008-01-03	Glaxo Group Limited	Phenyl- pyrazole derivatives, process for their preparation and their pharmaceutical use
GB0621978D0 (en) *	2006-11-03	2006-12-13	Chroma Therapeutics Ltd	Inhibitors of p38 mitogen-activated protein kinase
EP1992344A1 (en)	2007-05-18	2008-11-19	Institut Curie	P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
KR101529767B1 (ko)	2009-08-07	2015-06-17	추가이 세이야쿠 가부시키가이샤	아미노피라졸 유도체
JP2011201794A (ja) *	2010-03-24	2011-10-13	Fujifilm Corp	５−アミノピラゾール誘導体及びその塩の製造方法
JP5620417B2 (ja) *	2011-02-07	2014-11-05	中外製薬株式会社	アミノピラゾール誘導体を含む医薬
MX369974B (es) *	2013-09-03	2019-11-27	Sareum Ltd	Compuestos farmaceuticos.
JP6514645B2 (ja)	2013-12-27	2019-05-15	中外製薬株式会社	Ｆｇｆｒゲートキーパー変異遺伝子およびそれを標的とする医薬
US10479780B2 (en)	2015-06-17	2019-11-19	Chugai Seiyaku Kabushiki Kaisha	Aminopyrazole derivatives
GB201612238D0 (en)	2016-07-14	2016-08-31	Mereo Biopharma 1 Ltd	Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-Yl]-n-cyclopropyl-4-methylbenzamide
GB201612240D0 (en)	2016-07-14	2016-08-31	Mereo Biopharma 1 Ltd	Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide
WO2018059533A1 (zh) *	2016-09-29	2018-04-05	南京明德新药研发股份有限公司	p38αMAPK激酶抑制剂及其制备方法和应用
US10342786B2 (en)	2017-10-05	2019-07-09	Fulcrum Therapeutics, Inc.	P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
EP3692144A1 (en)	2017-10-05	2020-08-12	Fulcrum Therapeutics, Inc.	Use of p38 inhibitors to reduce expression of dux4
EP3563848A1 (en) *	2018-04-30	2019-11-06	S.I.S.S.A. Scuola Internazionale Superiore di Studi Avanzati	Serpin inhibitors for the treatment of prion and prion-like diseases
GB201815699D0 (en) *	2018-09-26	2018-11-07	Mereo Biopharma 1 Ltd	Synthetic method
GB201815695D0 (en) *	2018-09-26	2018-11-07	Mereo Biopharma 1 Ltd	Synthetic method
ES2974842T3 (es) *	2018-11-13	2024-07-01	Novartis Ag	Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de nlrp
US12134611B2 (en)	2018-11-13	2024-11-05	Novartis Ag	Compounds and compositions for treating conditions associated with NLRP activity

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2862374B2 (ja) *	1992-12-17	1999-03-03	フアイザー・インコーポレイテツド	Ｃｒｆアンタゴニスト活性を有するピラゾール及びピラゾロピリミジン

1999
- 1999-04-28 WO PCT/EP1999/002879 patent/WO1999057101A1/en not_active Ceased
- 1999-04-28 DE DE69924480T patent/DE69924480D1/de not_active Expired - Fee Related
- 1999-04-28 EP EP99923484A patent/EP1075467B1/en not_active Expired - Lifetime
- 1999-04-28 IL IL13916999A patent/IL139169A0/xx unknown
- 1999-04-28 HR HR20000724A patent/HRP20000724A2/hr not_active Application Discontinuation
- 1999-04-28 KR KR10-2000-7012375A patent/KR100404256B1/ko not_active Expired - Fee Related
- 1999-04-28 HU HU0101581A patent/HUP0101581A3/hu unknown
- 1999-04-28 ID IDW20002241A patent/ID27535A/id unknown
- 1999-04-28 BR BR9911013-0A patent/BR9911013A/pt not_active IP Right Cessation
- 1999-04-28 AU AU40348/99A patent/AU765030B2/en not_active Ceased
- 1999-04-28 CN CNB998060046A patent/CN1147476C/zh not_active Expired - Fee Related
- 1999-04-28 TR TR2000/03256T patent/TR200003256T2/xx unknown
- 1999-04-28 CA CA002329065A patent/CA2329065A1/en not_active Abandoned
- 1999-04-28 PL PL99344004A patent/PL344004A1/xx not_active Application Discontinuation
- 1999-04-28 NZ NZ507558A patent/NZ507558A/en unknown
- 1999-04-28 AT AT99923484T patent/ATE292118T1/de not_active IP Right Cessation
- 1999-04-28 JP JP2000547071A patent/JP3590586B2/ja not_active Expired - Fee Related
- 1999-04-28 YU YU67600A patent/YU67600A/sh unknown
- 1999-04-28 RU RU2000130199/04A patent/RU2000130199A/ru not_active Application Discontinuation
- 1999-05-03 MA MA25567A patent/MA26627A1/fr unknown
- 1999-05-05 TW TW088107268A patent/TW593282B/zh not_active IP Right Cessation
2000
- 2000-11-02 NO NO20005535A patent/NO317985B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
ID27535A (id)	2001-04-12
KR100404256B1 (ko)	2003-11-01
ATE292118T1 (de)	2005-04-15
KR20010043363A (ko)	2001-05-25
TR200003256T2 (tr)	2001-04-20
RU2000130199A (ru)	2002-11-10
PL344004A1 (en)	2001-09-10
CN1147476C (zh)	2004-04-28
EP1075467A1 (en)	2001-02-14
JP2002513784A (ja)	2002-05-14
JP3590586B2 (ja)	2004-11-17
HUP0101581A3 (en)	2002-07-29
CA2329065A1 (en)	1999-11-11
NO20005535L (no)	2000-11-02
YU67600A (sh)	2003-07-07
TW593282B (en)	2004-06-21
HRP20000724A2 (en)	2001-06-30
DE69924480D1 (en)	2005-05-04
EP1075467B1 (en)	2005-03-30
BR9911013A (pt)	2001-02-06
NZ507558A (en)	2003-08-29
NO20005535D0 (no)	2000-11-02
AU4034899A (en)	1999-11-23
AU765030B2 (en)	2003-09-04
HK1037374A1 (en)	2002-02-08
MA26627A1 (fr)	2004-12-20
WO1999057101A1 (en)	1999-11-11
HUP0101581A2 (hu)	2002-03-28
NO317985B1 (no)	2005-01-17
CN1300282A (zh)	2001-06-20

Publication	Publication Date	Title
PL344004A1 (en)	2001-09-10	Pyrazole derivatives as p-38 map kinase inhibitors
IL135302A0 (en)	2001-05-20	Bicyclic kinase inhibitors
MXPA02011320A (es)	2004-09-10	Derivados de pirazol triciclico como inhibidores de cinasa.
BR0014225A (pt)	2002-05-21	Derivados de pirazol
BG105481A (en)	2001-12-29	Tricyclic pyrazole derivatives
MXPA03010207A (es)	2004-03-10	Nuevas 4-anilinoquinolin-3-carboxamidas.
DE60112609D1 (en)	2005-09-15	Pyrazolopyridine
ATE316083T1 (de)	2006-02-15	Adamantanderivate
AU2003228770A8 (en)	2003-11-11	Substituted pyrazolopyrimidines
DE60112330D1 (en)	2005-09-01	Pyrazolopyridinderivate
MXPA05013076A (es)	2006-03-09	Compuestos de isoindolina-1-ona como inhibidores de cinasa.
IL145564A0 (en)	2002-06-30	Substituted 1,4-dihydroindeno [1,2-c] pyrazoles as inhibitors of tyrosine kinase
MXPA03001536A (es)	2004-05-04	(aminoalcoxibenzoil) benzofuranos o benzotiofenos, metodo para preparar los mismo y composiciones que los contienen.
AU2002357740A1 (en)	2003-06-23	Pyrazolo-pyridine derivatives as antiherpes agents
AU2002248531A1 (en)	2002-09-24	Pyrazolopyriadine derivatives
ECSP992945A (es)	2001-02-21	Derivados de pirazol